Syapse picked up $30 million in series D financing, funds it will use to scale its oncology precision medicine software.
Germano takes up the position 8 months after a shift in focus at Intrexon led him to give up the president post at the synthetic biology company.
Shares in Acorda Therapeutics are sliding following the news that the company’s Parkinson’s drug has been linked to a potentially fatal side effect.
The expansion of the deal gives the Roche subsidiary the chance to use Arvinas’ protein degradation technology against additional disease targets.
Fierce 15 winner Turnstone Biologics has poached Mike Burgess, MBChB, Ph.D., from Bristol-Myers Squibb to be its new head of R&D.
Using tech licensed from Yale University, Inozyme Pharma has emerged from stealth with $49 million and a mission.
Locus Biosciences is moving ahead with a first clinical trial for its CRISPR-based antimicrobial drugs—armed with $19 million in series A funding.
Loxo predicts the deal for its tropomyosin receptor kinase inhibitor franchise will generate $1 billion over the next few years.
The Parker Institute for Cancer Immunotherapy is sponsoring the trial, which will take place at the MD Anderson Cancer Center.
Flagship Pioneering has launched its latest biotech, Torque, as it hopes to power through using a new class of “deep-primed” immune cell therapies in cancer.